drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
First-in-human investigational immunotherapy designed to target the NY‑ESO‑1 antigen presented by HLA‑A2, aiming to elicit antigen-specific T‑cell–mediated anti-tumor responses in HLA‑A2–positive and/or NY‑ESO‑1–positive tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A TCR-mimetic bispecific that targets the NY‑ESO‑1 peptide presented by HLA‑A2 on tumor cells and engages T cells to drive antigen‑specific cytotoxic killing of HLA‑A2/NY‑ESO‑1–positive tumors.
drug_name
DS-2243a
nct_id_drug_ref
NCT06644755